- Jefferies upgraded Gland Pharma to hold with a target price of Rs 1,950 from Rs 1,350
- Citi maintained a sell rating with a target price of Rs 1,680 for Gland Pharma
- Gland Pharma's Q1 profit rose 50% and met operational expectations, driven by Cenexi turnaround
Brokerages are divided in their views on Gland Pharma Ltd., post first quarter of fiscal 2025-26. Jefferies has upgraded its rating to 'hold' from 'underperform' and hiked the target price to Rs 1,950 from Rs 1,350. Meanwhile, Citi has maintained a 'sell' rating, with a target price at Rs 1,680.
Jefferies upgradeed Gland Pharma to hold, as it believe earnings downcycle for the company is behind and in next 1-2 years can benefit from the generic GLP driven tailwinds. "Our FY26-27 EPS moves up by 2-5% on higher growth and margin profile. We value Gland at 25 times Sept. 27 EPS with our price target," it added.
-
NDTV Profit Ignite 2026 Live Updates: Tamannaah Bhatia Opens Up On Acting And Business -
Gold Price Dips Ahead Of Diwali: Can It Go Lower On Dhanteras? What To Expect -
What Would Make Brokers Bullish Again On Indian Markets? Axis Lists Its Triggers -
India's Market Leaders To Decode The New Samvat At NDTV Profit Ignite In Mumbai On Oct 28 -
NDTV Profit IGNITE Diwali 2026: Top Market Veterans Decode Wealth Creation -
NDTV Ignite, The Trillion-Dollar Trajectory: India's Road to 2030
The brokerage believes Gland Pharma's earnings have bottomed out but current valuations leave little upside.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The company's Q1 results were operationally in-line with Jefferies estimates driven by turnaround in Cenexi which benefitted from launch of higher value projects and better capacity utilisation.
The brokerage noted that the company's revenue is a miss but Cenexi breakeven leads to in-line Ebitda. "US growth below par but guidance strong for the year, as GLP helps to drive strong growth in core markets. Meanwhile, Europe growth is supported by new launches," it added.
Citi noted that commentary around GLP-1 Pen/Cartridge pickup may moderate Street expectations.
"Gland Pharma numbers were in-line as subdued performance in the base-line business has been offset by recovery in Cenexy, a key positive in the quarter," it added.
The brokerage highlighted management was upbeat on Cenexy outlook.
"The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin. Lairaglutide and Acetaminophen bags. The company is increasing GLP-1 pen capacity from 40m to 140m. However, a major ramp-up in FY29-30," it added.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
